Skip to main content

Invitrogen Execs Get Raises, Nanogen's Saltmarsh to Retire, BioTrove Names a CBO, and More

NEW YORK (GenomeWeb News) - Invitrogen has given company CFO David Hoffmeister a raise in base salary to $475,000, and has raised VP of R&D Claude Benchimol’s salary to $420,000, according to a filing with the US Securities and Exchange Commission. The raises will take effect at the beginning of the year, the company said.

Richard Hughes of the London-based healthcare and diagnostics company Lab21 has been bumped up to head of sales and marketing and has been elected to sit on the company’s executive management team. Hughes will report directly to company CEO Graham Mullis

AlgoNomics has promoted Philippe Stas to the head office as CEO, and the previous CEO, Ignace Lasters, will retain the role of CSO. Stas has been serving as COO and he is chairman of the Belgian Association of Bioindustries.

Robert Saltmarsh, VP and CFO at Nanogen, plans to retire at the end of February 2008, the company stated in an SEC filing. Nanogen also said that Nicholas Venuto, who is currently executive director of finance, will take over Saltmarsh’s duties in both positions. Nanogen also has given Venuto a hike in base salary to $220,000 and granted him the option to buy 100,000 shares of the company’s common stock.

WellGen has appointed Nancy Rawson to the newly created CSO position. Rawson comes to the company from the Monell Chemical Senses Center, located in Philadelphia, where she was an associate member. Rawson also formerly was a senior nutrition research associate at the Campbell Soup Company.

ESA Biosciences has tapped Jasmine Gruia-Gray to be VP of life sciences marketing. Gruia-Gray previously was at Amersham Biosciences, where she was director of marketing for protein sciences and protein characterization. Before her time at Amersham, Gruia-Gray was a science coordinator and research assistant at the New York University Medical Center/Salk School of Science.

Gene Express has appointed David Johnston to its scientific advisory board. Johnston is VP and chief scientific officer at Esoterix Clinical Trials Services, a division of Laboratory Corporation of America. Johnston also formerly was in R&D leadership positions at LabCorp.

BioTrove has named Edward Sztukowski to be senior VP and chief business officer. Sztukowski will manage business operations in the company’s molecular diagnostics business and will push growth for the company’s technologies.
Sztukowski formerly was a senior VP and business area manager at bioMerieux and he was president of Remel and held sales and marketing positions at Abbott Laboratories Diagnostics Division. He also is a member of the scientific advisory board at Expression Analysis.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.